Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Abroad (travel likely)RecruitingPHASE1

Conditions

AML · Refractory/Relapse Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University People's Hospital, Beijing, China
Contact: Study coordinator (Meng Lv, M.D,Ph.D) · drlvmeng@bjmu.edu.cn · 010-88316617
Contact: Principal Investigator (Xiangyu Zhao, M.D, Ph.D)
Meng Lv, M.D, Ph.D (Sub-investigator)

Study leads

XiangYu Zhao, M.D, Ph.D
Principal Investigator
Peking University People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Acute Myeloid Leukemia · Pediatric AML

Abroad (travel likely)RecruitingEARLY_PHASE1

Houston, United States

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Hematologic Malignancy · Acute Leukemia · Remission

Abroad (travel likely)RecruitingPHASE2

Minneapolis, United States

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Acute Lymphoblastic Leukemia · Acute Leukemias · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Manchester, United Kingdom

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Duarte, United States